Banner
targets (2)
for drugs
Identification
Name Cromoglicic acid
Accession Number DB01003 (APRD00336)
Type small molecule
Groups approved
Description

A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. [PubChem]
Structure Thumb
Download: MOL | SDF | SMILES | InChI
Display: 2D Structure | 3D Structure
Synonyms
Acide Cromoglicique [INN-French]
Acido Cromoglicico [INN-Spanish]
Acidum Cromoglicicum [INN-Latin]
Cromoglicate
Cromoglicic Acid
Cromoglycate
Cromolyn
Salts Not Available
Brand names
Name Company
Aarane
Alercom
Alerion
Allergocrom
Colimune
Crolom
Cromo-Comod
Cromoptic
Cromovet
Fivent
Gastrocrom
Gastrofrenal
Inostral
Intal
Introl
Irtan
Lomudal
Lomupren
Lomusol
Lomuspray
Nalcrom
Nalcron
Nasalcrom
Nasmil
Opticrom
Opticron
Rynacrom
Sofro
Vistacrom
Vividrin
First Prev Next Last
Brand mixtures Not Available
Categories
  • Anti-Asthmatic Agents
CAS number 16110-51-3
Weight Average: 468.3665
Monoisotopic: 468.069261354
Chemical Formula C23H16O11
InChI Key InChIKey=IMZMKUWMOSJXDT-UHFFFAOYSA-N
InChI
InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
Plain Text
IUPAC Name
5-{3-[(2-carboxy-4-oxo-4H-chromen-5-yl)oxy]-2-hydroxypropoxy}-4-oxo-4H-chromene-2-carboxylic acid
SMILES
OC(COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O)COC1=CC=CC2=C1C(=O)C=C(O2)C(O)=O
Plain Text
Mass Spec Not Available
Taxonomy
Kingdom Not Available
Classes Not Available
Substructures Not Available
Pharmacology
Indication For the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
Pharmacodynamics Cromoglicate or cromolyn (USAN), a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Cromoglicate is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis.
Mechanism of action Cromoglicate inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Cromoglicate also may reduce the release of inflammatory leukotrienes. Cromoglicate may act by inhibiting calcium influx.
Absorption 1%
Volume of distribution Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life 1.3 hours
Clearance Not Available
Toxicity Symptoms of overdose include cough, nasal congestion, nausea, sneezing and wheezing.
Affected organisms
  • Humans and other mammals
Pathways Not Available
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Sanofi aventis us llc
  • Ucb inc
  • Genera pharmaceuticals llc
  • Azur pharma international ltd
  • Bausch and lomb pharmaceuticals inc
  • Akorn inc
  • Alcon laboratories inc
  • Novex pharma
  • Allergan inc
  • Actavis mid atlantic llc
  • Dey lp
  • Pharmascience inc
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
  • L perrigo co
  • Qpharma llc
  • Blacksmith brands inc
Packagers
Dosage forms
Form Route Strength
Aerosol, metered Respiratory (inhalation)
Capsule Oral
Liquid Ophthalmic
Solution Ophthalmic
Solution Respiratory (inhalation)
Spray Nasal
Prices
Unit description Cost Unit
Cromolyn Sodium 4% Solution 10ml Bottle 38.74 USD bottle
Cromolyn sodium powder 9.49 USD g
Intal inhaler 5.77 USD g
Crolom 4% eye drops 4.46 USD ml
Gastrocrom 100 mg/5ml Concentrate 5ml Ampule 3.92 USD ampule
Cromolyn 4% eye drops 3.65 USD ml
Cromolyn Sodium 20 mg/2ml Neb. Solution 2ml Plastic Container 1.73 USD plastic
Nalcrom 100 mg Capsule 1.54 USD capsule
Gastrocrom 100 mg/5 ml conc 0.78 USD ml
Nasalcrom 4% spray 0.66 USD ml
Cromolyn sodium nasal solution 0.49 USD ml
CVS Pharmacy cromolyn sod nasal solutn 0.31 USD ml
Pms-Sodium Cromoglycate 1 % Solution 0.27 USD ml
Introl 75% solution 0.13 USD ml
First Prev Next Last
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents Not Available
Properties
State solid
Experimental Properties
Property Value Source
melting point 241 dec °C PhysProp
water solubility 210 mg/L Not Available
logP 1.92 POMONA (1987)
pKa 1.1 SANGSTER,J (1993)
Predicted Properties
Property Value Source
water solubility 3.58e-02 g/l ALOGPS
logP 1.84 ALOGPS
logP 1.48 ChemAxon
logS -4.1 ALOGPS
pKa (strongest acidic) 1.77 ChemAxon
pKa (strongest basic) -3.4 ChemAxon
physiological charge -2 ChemAxon
hydrogen acceptor count 11 ChemAxon
hydrogen donor count 3 ChemAxon
polar surface area 165.89 ChemAxon
rotatable bond count 8 ChemAxon
refractivity 114.11 ChemAxon
polarizability 44.38 ChemAxon
References
Synthesis Reference Not Available
General Reference
  1. Heinke S, Szucs G, Norris A, Droogmans G, Nilius B: Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br J Pharmacol. 1995 Aug;115(8):1393-8. Pubmed
External Links
Resource Link
KEGG Drug D07753 Link_out
KEGG Compound C06928 Link_out
ChEBI 59773 Link_out
ChEMBL 59773 Link_out
Therapeutic Targets Database DAP000819 Link_out
PharmGKB PA449138 Link_out
Drug Product Database 2231671 Link_out
RxList http://www.rxlist.com/cgi/generic/cromolyn.htm Link_out
Wikipedia http://en.wikipedia.org/wiki/Cromoglicate Link_out
ATC Codes
  • R01AC01
  • A07EB01
  • S01GX01
  • R03BC01
AHFS Codes
  • 48:10.32
PDB Entries Not Available
FDA label Not Available
MSDS show (58.3 KB)
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Targets

1. Calcium-activated potassium channel subunit alpha 1

Pharmacological action: yes
Actions: inhibitor

Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX)

Organism class: human
UniProt ID: Q12791 Link_out
Gene: KCNMA1 Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Protein S100-P

Pharmacological action: unknown
Actions: antagonist
Organism class: human
UniProt ID: P25815 Link_out
Gene: S100P Link_out
Protein Sequence: FASTA
Gene Sequence: FASTA
SNPs: SNPJam Report Link_out

References:
  1. Arumugam T, Ramachandran V, Logsdon CD: Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. Pubmed
Comments
Drug created on June 13, 2005 07:24 / Updated on February 08, 2013 16:19